BIOXCEL THERAPEU

BTAI NASDAQ
10.90
-0.03
-0.23%
Closed 16:00 06/14 EDT
Open
11.10
Prev Close
10.93
High
11.12
Low
10.84
Volume
34.06K
Avg Vol (3M)
37.11K
52 Week High
14.79
52 Week Low
2.410
% Turnover
0.22%
Market Cap
170.76M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers BIOXCEL THERAPEU BTAI stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. The Company uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer.
MORE >

Recently

Name
Price
%Change